Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia

TL;DR

This study shows that a lower dose of venetoclax with specific drugs is as effective as higher doses in treating acute myeloid leukemia.

Contribution

The study provides real-world evidence that a lower venetoclax dose with azole drugs maintains treatment efficacy in AML.

Findings

HMA + VEN50 with posaconazole or voriconazole achieves similar response rates to higher venetoclax doses.

Reducing venetoclax to 50 mg with azole drugs does not compromise treatment efficacy in AML patients.

Comparable responses were observed with either azole drug when combined with HMA and VEN50.

Abstract

Real‐world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited.

We evaluated outcomes of patients with newly‐diagnosed AML treated with HMA + VEN50 with either posaconazole (n = 23) or voriconazole (n = 95).

We report that treatment with HMA + VEN50 with either azole elicits a response rate similar to that described in the VIALE‐A trial. Reducing the VEN dose to 50 mg with either strong CYP3A4 inhibitor did not compromise on the efficacy of the combination.

HMA + VEN50 with either posaconazole or voriconazole yields comparable responses to higher doses of VEN reported previously.

The authors have confirmed clinical trial registration is not needed for this submission.